This week in therapeutics




Licensing status

Publication and contact information

Endocrine/metabolic disease


v-Maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA; RIPE3b1); microRNA-204 (miR-204)

Mouse and cell culture studies suggest inhibiting miR-204 could help treat diabetes. In a mouse model of type 2 diabetes, miR-204 expression in islets was greater than that in islets from lean control mice. In an islet b cell line and in primary human islets, miR-204 overexpression decreased insulin expression and levels of the insulin regulator MAFA compared with wild-type expression. Next steps include developing and optimizing miR-204 inhibitors.

SciBX 6(37); doi:10.1038/scibx.2013.1030
Published online Sept. 26, 2013

Patent application filed covering use in diabetes; available for licensing from the UAB Research Foundation

Xu, G. et al. Nat. Med.;
published online Aug. 25, 2013;
Contact: Anath Shalev,
The University of Alabama at Birmingham, Birmingham, Ala.